2016 Press Releases

Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
07/18/16Seattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS® (Brentuximab Vedotin) Monotherapy Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Classical Hodgkin Lymphoma in Blood
-Estimated Five-Year Overall Survival Rate was 41 Percent and Five-Year Progression-Free Survival Rate was 22 Percent--Patients Who Achieved a Complete Remission Had Estimated Five-Year Overall Survival of 64 Percent and Five-Year Progression-Free Survival of 52 Percent-BOTHELL, Wash., CAMBRIDGE, Mass. and OSAKA, Japan, July 18, 2016 – Seattle Genetics, Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced the final data of the ADCETRIS (brentuximab vedotin) mon... 
Printer Friendly Version
07/13/16Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2016 Financial Results on July 26, 2016
BOTHELL, Wash.--(BUSINESS WIRE)--Jul. 13, 2016-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter 2016 financial results on Tuesday, July 26 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access... 
Printer Friendly Version
07/06/16Seattle Genetics Announces European Commission Approval of ADCETRIS® (Brentuximab Vedotin) as Consolidation Treatment in Post-Transplant Hodgkin Lymphoma
-Marketing Authorization Granted Based on Phase 3 AETHERA Clinical Trial Results- -Label Expansion Represents Third Indication for ADCETRIS in the European Union; AETHERA is the First of Four Phase 3 Clinical Trials Intended to Broaden the Global Use of ADCETRIS in CD30-Expressing Lymphomas- BOTHELL, Wash.--(BUSINESS WIRE)--Jul. 6, 2016-- Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that its collaborator Takeda Pharmaceu... 
Printer Friendly Version
06/11/16Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association
-Phase 1 Clinical Data Featured in Press Program and Oral Presentation Demonstrate 76 Percent Objective Response Rate, Including a 41 Percent Complete Remission Rate, in Newly Diagnosed AML Patients Treated with 33A Combination Therapy- -Data Support Recently Initiated Phase 3 CASCADE Study Evaluating 33A in Combination with Hypomethylating Agents in AML Patients- COPENHAGEN, Denmark, June 11, 2016 /PRNewswire/ -- Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted data at the 21s... 
Printer Friendly Version
06/06/16Seattle Genetics and Astellas Present ASG-15ME and Enfortumab Vedotin Phase I Clinical Data in Metastatic Urothelial Cancer at ASCO Annual Meeting
-Clinical Data Indicating Antitumor Activity Presented from Two Antibody-Drug Conjugate Programs- CHICAGO & TOKYO--(BUSINESS WIRE)--Jun. 6, 2016-- Seattle Genetics, Inc. (NASDAQ:SGEN) and Astellas Pharma Inc. (TOKYO:4503) today presented first clinical data for ASG-15ME and enfortumab vedotin (ASG-22ME) at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting being held June 3-7, 2016, in Chicago, IL. This Smart New... 
Printer Friendly Version
05/25/16Seattle Genetics Initiates Pivotal Phase 3 Trial of Vadastuximab Talirine (SGN-CD33A) for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
-The Phase 3 Study, Called CASCADE, will Evaluate 33A in Combination with Hypomethylating Agents in Older AML Patients- -Data Presented at the 2015 American Society of Hematology Annual Meeting Demonstrated Encouraging Anti-leukemic Activity and Support Advancing 33A into a Registrational Trial- -Additional 33A Phase 1 Data to be Featured in an Oral Presentation at the European Hematology Association Congress in June 2016- BOTH... 
Printer Friendly Version
05/04/16Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--May 4, 2016-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from the Seattle Genetics website at www.seattlegenetics.com in the Investors and News section. Bank of America Merrill Lynch 2016 Health Care Conference Wednesday, May 11, 11:20 a.m. Pacific Ti... 
Printer Friendly Version
04/28/16Seattle Genetics Reports First Quarter 2016 Financial Results
-Record First Quarter 2016 Revenues of $111.2 Million, Including $58.6 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Sales- -Top-Line Data from ADCETRIS Phase 3 ALCANZA Trial Expected in Third Quarter of 2016- -Vadastuximab Talirine (SGN-CD33A) Phase 3 Trial Initiation Planned by Third Quarter of 2016- -First Clinical Data from ASG-15ME and ASG-22ME Phase 1 Trials to be Presented at ASCO- ... 
Printer Friendly Version
04/18/16Seattle Genetics Highlights Data Supporting Antibody-Drug Conjugate and Novel Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 18, 2016-- Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted multiple data presentations that support several of the company’s antibody-drug conjugate (ADC) and immuno-oncology programs featured at the upcoming 107th Annual Meeting of the American Association for Cancer Research (AACR) being held April 16 through 20, 2016 in New Orleans, LA. The presentations describe preclinical data with SGN-LIV1A and ... 
Printer Friendly Version
04/17/16Seattle Genetics Highlights Novel Antibody-Drug Conjugate (ADC) Technology Advances at the American Association for Cancer Research (AACR) Annual Meeting
-Innovative Research Demonstrates Seattle Genetics’ Leadership in Empowered Antibodies- BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 17, 2016-- Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted novel antibody-drug conjugate (ADC) technology advances presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR) being held April 16 through 20, 2016 in New Orleans, LA. Data in multiple presentations demonstrat... 
Printer Friendly Version
04/07/16Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2016 Financial Results on April 28, 2016
BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 7, 2016-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2016 financial results on Thursday, April 28 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access... 
Printer Friendly Version
03/01/16Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Mar. 1, 2016-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. Cowen and Company 36th Annual Health Care Conference Tuesday, March 8, 11:20 a.m. Eastern Time, Bost... 
Printer Friendly Version
02/25/16Seattle Genetics Initiates Phase 1 Trial of SGN-CD19B for Patients with B-cell Non-Hodgkin Lymphoma
-SGN-CD19B, A Novel Antibody-Drug Conjugate (ADC) Utilizing Seattle Genetics’ Newest ADC Technology, Demonstrated Strong Preclinical Antitumor Activity in B-cell Malignancies in Data Presented at the 2015 American Society of Hematology Annual Meeting- BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 25, 2016-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced initiation of a phase 1 clinical trial of SGN-CD19B for relapsed or refractory patients with... 
Printer Friendly Version
02/22/16Seattle Genetics Initiates Phase 1/2 Trial of Vadastuximab Talirine (SGN-CD33A) Combination Therapy for Patients with Untreated Myelodysplastic Syndrome (MDS)
-Broad 33A Clinical Development Program Underway in Acute Myeloid Leukemia (AML) and MDS- BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 22, 2016-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced initiation of a phase 1/2 clinical trial of vadastuximab talirine (SGN-CD33A; 33A) in combination with azacitidine (Vidaza) in patients with previously untreated myelodysplastic syndrome (MDS). 33A is an antibody-drug conjugate (ADC) targeted to C... 
Printer Friendly Version
02/09/16Seattle Genetics Reports Fourth Quarter and Year 2015 Financial Results
-Total 2015 Revenues of $336.8 Million, Including $226.1 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Product Sales- -Total 2016 Revenues Expected to Increase to a Range of $390 Million to $430 Million, Including ADCETRIS U.S. and Canada Net Sales of $255 Million to $275 Million- -Vadastuximab Talirine (SGN-CD33A) Phase 3 Trial Initiation Planned by Third Quarter of 2016- -Data from ADCETRIS Phase 3... 
Printer Friendly Version
02/04/16Seattle Genetics Announces Commercial and Regulatory Progress under ADCETRIS® (Brentuximab Vedotin) Collaboration with Takeda
-$20 Million Milestone Payment Triggered by Annual ADCETRIS Net Sales Exceeding $200 Million in Takeda’s Territory During 2015- -European Commission Recently Approved a Type II Label Variation that Includes Data on the Retreatment of Relapsed or Refractory (R/R) Hodgkin lymphoma or R/R Systemic ALCL- BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 4, 2016-- Seattle Genetics, Inc., (Nasdaq: SGEN) today announced that it will receive a one-time $2... 
Printer Friendly Version
01/20/16Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2015 Financial Results on February 9, 2016
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 20, 2016-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its fourth quarter and year 2015 financial results on Tuesday, February 9 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: ... 
Printer Friendly Version
01/05/16Seattle Genetics to Present at the J.P. Morgan Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 5, 2016-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2016 at 2:30 p.m. Pacific Time. Both the presentation and question and answer session that follows at 3:00 p.m. will be webcast live and available for replay from Seattle Genetics’ website at www.seat... 
Printer Friendly Version